Abstract Submission Deadline: Dec 16, 2025 - Don’t miss out – Early Bird Registration closes on Dec 18, 2025 - Submit your abstract and secure your spot today!
Abstract Submission Deadline: Dec 16, 2025 - Don’t miss out – Early Bird Registration closes on Dec 18, 2025 - Submit your abstract and secure your spot today!
C2P Forum proudly presents the 2nd European Congress on Rare Diseases and Orphan Drugs, set to take place on September14-15, 2026 in London, UK. This two-day event uniting researchers, clinicians, industry leaders, policymakers, and patient advocates from across the globe.
This congress will provide a dynamic platform to explore the latest innovations, challenges, and breakthroughs in rare disease research and orphan drug development. With the aim of fostering collaboration, raising awareness, and accelerating progress, the event will highlight real-world solutions to improve the lives of those affected by rare diseases.
The program will feature keynote lectures, plenary sessions, panel discussions, interactive workshops, and networking opportunities, along with an exhibition showcasing emerging technologies and therapies.
Altogether Euro Rare Diseases is a key event focused on advancing research, encouraging innovation, and enhancing the well-being of people living with rare diseases.
Join us in London for an inspiring gathering that will advance research, strengthen partnerships, and shape the future of rare disease care and global health. Register now to secure your place at this landmark event!
Abstract Submission Deadline: Dec 16, 2025
Early Bird Deadline: Dec 18, 2025
Mid Term Deadline: Feb 27, 2025
Final/Onsite Registration: Sep 14, 2025
The Rare Disease and Orphan Drugs Journal (RDODJ) is a peer-reviewed, open-access journal published quarterly by OAE Publishing Inc. Launched in April 2021, it is indexed in ESCI and is expected to receive its first Impact Factor in June 2026.
RDODJ publishes research addressing regulatory, socio-economic, and human science aspects of rare diseases and orphan drugs. The Editor-in-Chief is Prof. Daniel Scherman (Paris University, Fondation Maladies Rares).
RDODJ will report on scientific advances in the genetics of rare diseases, the molecular basis of the pathologies, and translational research on diagnosis, prevention and treatment.
In addition, RDODJ aims to provide a forum for scientific studies and discussion covering the important regulatory, socio-economic and human science issues related to rare diseases and orphan drugs.
The ultimate objective of RDODJ is to promote the dissemination of research results and scientific discussion among the research community, practitioners, and patient-advocacy organizations.
Journal URL:
https://www.oaepublish.com/rdodj/
The Journal of Translational Genetics and Genomics is an open access international journal promoting the translation of basic research into clinical practice. The aims of the journal are to publish high quality, original, peer-reviewed research articles of discoveries in the area of genetics and genomics. Coverage extends, but not limited to, the basic and clinical studies related to human genetics including molecular and clinical genetics, biochemistry, molecular signaling, epigenetics, pharmaceutical sciences, pharmacogenomics, molecular biology, pharmacology and oncology. The journal also emphasizes on the development of clinical potential and application of new therapeutics, disease-specific biomarkers, cellular and molecular medicine, bioinformatics, artificial intelligence, drug application, and health policy. Manuscript of interest on clinical implications for the prevention and treatment of diseases will be given preference.
The article types include original research, review, meta-analysis, systematic review, technical notes, commentary, letter to editor, opinion, perspective and editorial.
Journal URL:
C2P Forum is pleased to announce the successful completion of the European Congress on Rare Diseases and Orphan Drugs, held on November 17-18, 2025, in Rome, Italy.
The conference, themed “Pioneering Care for the Few: Novel Insights into Rare Diseases and Orphan Therapies,” concluded with great success.
We extend our sincere gratitude to the esteemed scientists, distinguished researchers, students and professionals from universities, research institutions, companies, and laboratories worldwide who contributed their latest insights and expertise in the field of Climate change and environmental sustainability.
The conference featured a dynamic program, including keynote addresses, oral presentations, poster sessions, and video presentations. The event was marked by significant engagement and outstanding contributions, and we are delighted to share some of the key highlights presented during the sessions:
We would like to express our sincere appreciation to our Session Chairs J Paul Seale, Augusta University, USA, Jorge Sales Marques, Hospital Cuf Porto, Portugal, Gulsen Meral, Nisantasi University, Turkey & Epigenetic Coaching, UK
Building on the success of the Euro Rare Diseases 2025, we are pleased to announce our upcoming event, 2nd European Congress on Rare Diseases and Orphan Drugs on September 14-15, 2026 in London, UK
More info: https://rarediseases.c2pforum.com/
Huge thanks to all the delegates! Your energy and involvement made this event a big success!
Mark your calendars and set your reminders.
Hope to meet you again in London, UK!!